Gaining critical characterization insights for development of CAR-T Therapies for Solid Tumors
Published: April 17, 2019
Planning for Success: Emerging GMP-Grade Raw Materials & Technologies for Cell Therapy
Published: April 15, 2019
Cell Therapy Quality/CMC & Analytics – Full Spotlight
Published: February 21, 2019
European regulator’s perspective: best practice & future directions in cell therapy CMC
Published: February 15, 2019
Commercial Lessons for Clinical Success
Published: February 4, 2019
Management of ‘out of specification’ commercial autologous CAR-T cell products
Published: December 17, 2018
Joined-up thinking: success criteria for tomorrow’s viral vector production platforms
Published: December 3, 2018
New Gene Therapy CMC Guidance from the FDA – A Breakthrough in Regulation or Something More Generic?
Published: August 15, 2018
Accelerated Access of Advanced Regenerative Therapies: an Industry Perspective
Published: August 6, 2018
Breakthrough Therapy Designation & Regenerative Medicine Advanced Therapy Designation Programs in Cellular & Gene Therapies
Published: July 30, 2018
The Regulatory Environment for Cell Therapies in Australia – an Opportunity to Expedite Clinical Development
Published: July 30, 2018
Experiences from Japan – SAKIGAKE Designation System for Regenerative Medical Products
Published: July 17, 2018
Proposed Solutions to Further Improve the Regulatory Landscape for ATMPS in Europe
Published: July 17, 2018
Nohla Therapeutics bags $56 million in Series B financing to fund cell therapy platform
Published: July 16, 2018
Drugs targeting interleukin-1 could eradicate cytokine release syndrome seen in CAR-T therapies
Published: June 8, 2018
Introducing controllable switches could improve the safety profile of CAR-T therapy
Published: June 1, 2018
Bluebird bio’s stem cell-gene therapy receives FDA’s breakthrough therapy designation
Published: May 29, 2018
Cellectis’ off-the-shelf CAR-T therapy trial to proceed with amended protocol
Published: May 23, 2018
